DVI News and Events
April 13, 2016
What's the process behind vaccine registration and policies for use? Here we share an overview of the different considerations involved at the local, regional and global level. At a country-level, vaccine manufacturers are given a marketing authorization (also known as a license or registration) by a national regulatory authority (NRA), which permits commercialization of the registered product within the country. NRAs register vaccines based on an evaluation of the quality of the...
April 07, 2016
Dengue, also known as breakbone fever, is a painful and sometimes fatal viral disease transmitted by theAedes aegypti mosquito. Dengue fever typically impacts urban environments in tropical and subtropical regions. There is no specific medication or cure available for dengue. Without proper treatment of symptoms, fatality rates of the severe forms, such as hemorrhagic fever, can exceed 20 percent. Dengue prevention efforts to date have focused on vector control, through insecticide...
September 14, 2015
By Dagna Constenla, Gatien de Broucker, Jorge Martin del Campo and Alexandra Greenberg IVAC at Johns Hopkins University The successful introduction of a vaccine in affected countries depends heavily on issues such as supply constraints, potential demand, and the impact of policy decisions on future demand and supply. Strategic demand forecasts (SDFs) play a central role in enabling vaccine suppliers, donors, and country-level stakeholders to make informed decisions about vaccine supply,...
How to Fight a Mosquito that Costs over $2 Billion in the Americas -- Expert Conclusions from Meeting in Bogota
August 31, 2015
Earlier this year, DVI convened the Americas Dengue Prevention Board along with scientists, global health experts, mathematical modelers and representatives of dengue vaccine manufacturers to discuss updates in dengue vaccines and vaccine introduction. Held in Bogota at the Colombian National Institute of Health (Institituto Nacional de Salud – INS), the meeting was instrumental given the new available clinical trial data, particularly the results of the first Phase 3 trials ever...
Dengue in Sri Lanka: Burden, Challenges and Prevention Strategies -- An Exclusive Interview with Dr. Hasitha Tissera
May 20, 2015
Dr. Tissera received his bachelor’s degree in medicine and surgery in 1995 and his residency training in the Provincial General Hospital in the remote mountainous region of Badulla. After being posted in to Ampara, the District capital city of the then war-torn eastern province in Sri Lanka, he learned about the basics in public health, in a new light -- hands on, under ongoing civil unrest and hostilities. Dr. Tissera joined the Central Epidemiology Unit subsequently, and in 2005...
March 04, 2015
In November of 2014, DVI held a two-day meeting to discuss the status of a dengue vaccine and exchange views on its licensure and introduction. Members of the Asia-Pacific Dengue Prevention Board (DPB), modelers of the impact of vaccination on dengue, public health specialists and dengue vaccine candidate representatives contributed to these important conversations. The meeting, held in Seoul, South Korea, consisted of four main activities. Participants reviewed the clinical development...
New DVI Report on Americas Dengue Prevention Board Meeting focused on Integrating Control Strategies
September 25, 2014
This year’s Americas Dengue Prevention Board (DPB) convened in Mexico City from March 25–26. The meeting’s objective was to assess the feasibility and benefits of integrating dengue vector-control strategies with an upcoming dengue vaccine. DVI compiled a summary of the discussions and recommendations from the Board in a new report you can access here. The meeting brought together vaccine and vector control experts, researchers, representatives of ministries of health...
September 15, 2014
Titled, “New chapter unfolding in the fight against dengue with an unwritten ending,” the Dengue Vaccine Initiative’s (DVI) editorial just published in the October issue of Transactions of the Royal Society of Tropical Medicine and Hygiene discusses the results of Sanofi’s dengue vaccine candidate Phase 3 trial in Asia. DVI experts explain that while these results show promising indications that a safe dengue vaccine is technically feasible, key questions remain...
September 05, 2014
The Prerelease On Wednesday, Sanofi Pasteur published a press release with preliminary results of the second arm of the Phase 3 trial of its candidate dengue vaccine. The trial was conducted in Brazil, Colombia, Honduras, Mexico, and Puerto Rico and involved 20,875 children and teenagers aged 9 to 16. The announcement follows a series of updates made through the year about a previous similar, though smaller in size, Phase 3 trial conducted in Indonesia, Malaysia, the Philippines,...
July 10, 2014
Please click here for the Dengue Vaccine Initiative (DVI) full statement. Today, July 10, Sanofi Pasteur published in The Lancet the results of the first of two Phase 3 clinical trials for its dengue vaccine candidate — a live attenuated chimeric tetravalent vaccine. The study is a randomized, observer-blind, placebo-controlled multicenter trial involving 10,275 children aged 2 to 14 years in Indonesia, Malaysia, the Philippines, Thailand and Vietnam. An Initial Examination of...